Isothiocyanate functional surfactants, formulations incorporating isothiocyanate functional surfactants and associated methods for treating biofilms

• US 10,287,246 B2
• Filed: 02/07/2018
• Issued: 05/14/2019
• Est. Priority Date: 01/03/2011
• Status: Active Grant

• Current Assignee: The William M. Yarbrough Foundation
• Original Assignee: The William M. Yarbrough Foundation
• Inventors: Silver, Michael E.
• Primary Examiner(s): Neagu, Irina
• Application Number:
  US15/890,578
• Publication Number:
  US 20180162811A1
• Time in Patent Office: 461 Days
• Field of Search: 514514, 514562, 514563, 514625, 514663, 514665, 558 17
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/145 having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2) isothiourea A61K31/155
• CPC Class Codes: A61K 31/198 Alpha-amino acids, e.g. alanine or edetic acid [EDTA] betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00
• CPC Class Codes: A61K 31/26 Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 47/34 Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers A61K47/10 takes precedence
• CPC Class Codes: A61K 9/0014 Skin, i.e. galenical aspects of topical compositions non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00
• CPC Class Codes: A61K 9/06 Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels composition of ointments, creams or gels A61K47/00
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: C07C 331/20 of a saturated carbon skeleton

Abstract

The present invention relates to methods, formulations, and compositions for the treatment of biofilms. In particular, the application discloses isothiocyanate functional surfactants either alone or combination with adjunct agents to treat biofilms. One suitable isothiocyanate functional surfactant is represented by the following chemical structure:

Claims

1. A method, comprising the step of administering to a patient having a biofilm a composition comprising an isothiocyanate functional surfactant, wherein the protonated form of the isothiocyanate functional surfactant is represented by the following chemical structure:

2. The method according to claim 1, wherein the composition comprising the isothiocyanate functional surfactant is administered to the patient at least one of orally, intravenously, intramuscularly, intrathecally, cutaneously, subcutaneously, transdermally, sublingually, buccally, rectally, vaginally, ocularly, otically, and nasally.

3. The method according to claim 1, wherein the composition comprising the isothiocyanate functional surfactant is topically administered to the patient.

4. The method according to claim 3, wherein the amount of isothiocyanate functional surfactant in the composition topically administered to the patient ranges from approximately 0.5 nmol/cm2 to approximately 10 μ

mol/cm2.

5. The method according to claim 4, wherein the composition comprising the isothiocyanate functional surfactant is a topical preparation selected from the group consisting of ointment, cream, emulsion, lotion and gel.

6. The method according to claim 5, wherein the composition further comprises one or more pharmaceutical, biological or molecular biological active agents.

7. The method according to claim 6, wherein the patient is a mammal.

8. The method according to claim 7, wherein the mammal is a human.